Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypersensitivity Reactions: Cytolytic Reactions01:01

Hypersensitivity Reactions: Cytolytic Reactions

Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
Complement System01:27

Complement System

The complement system is a group of approximately 20 plasma proteins that strengthen the body's defenses against infections through opsonization, inflammation, and cell lysis. Opsonization involves coating pathogens with complement proteins, making them more recognizable and facilitating phagocyte engulfment. Certain complement proteins induce inflammation that attracts immune cells to the site of infection. Cell lysis involves the destruction of pathogens through the formation of a membrane...
Disorders of Hemostasis01:24

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Disorders of Erythrocytes01:27

Disorders of Erythrocytes

Disorders of erythrocytes, or red blood cells (RBCs), include a range of conditions affecting their number, shape, or function.
Erythrocyte disorders can be broadly categorized into two main types: anemic and polycythemic conditions.
A low oxygen-carrying capacity of the blood due to the loss, lower production, or destruction of erythrocytes is termed anemia. Hemorrhagic anemia, for example, occurs when bleeding from an external wound or internal ulcer reduces erythrocyte counts.
On the other...
Humoral Immune Responses01:36

Humoral Immune Responses

Overview
Hypersensitivity Reactions: Immune-Complex Reactions01:19

Hypersensitivity Reactions: Immune-Complex Reactions

Type III hypersensitivity reactions occur when antigen–antibody complexes form and activate the complement system. Normally, these complexes help the clearance of antigens by phagocytes and red blood cells. However, when large numbers of immune complexes are present, they can deposit in tissues—particularly in the walls of blood vessels—leading to inflammation and tissue injury. These deposits trigger complement activation and neutrophil recruitment, resulting in serum sickness, a systemic...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neonatal continuous kidney replacement therapy.

Pediatric nephrology (Berlin, Germany)·2026
Same author

Addressing the urgent need for clinical workload reform-a statement from the American Society of Pediatric Nephrology (ASPN).

Pediatric nephrology (Berlin, Germany)·2026
Same author

Metabolic complications of citrate anticoagulation in continuous renal replacement therapy (crrt): a delphi consensus on indications, monitoring and management.

Critical care (London, England)·2026
Same author

Corrigendum to "Understanding Carpediem Indications and Outcomes: A Report from the ICONIIC Learning Network" The Journal of Pediatrics, Volume 288 (2026), 114838.

The Journal of pediatrics·2026
Same author

Dialysis modality and mortality of the Contemporary Infant and Neonatal Dialysis (COINED) Cohort: a Pediatric Nephrology Research Consortium (PNRC) study.

Pediatric nephrology (Berlin, Germany)·2026
Same author

Infant Renal Replacement Therapy Using Carpediem: A Multicenter Observational Cohort Study from the ICONIIC Learning Network.

The Journal of pediatrics·2025
Same journal

For health, for beauty, or both? navigating trends as adolescent clinicians.

Current opinion in pediatrics·2026
Same journal

Childhood sleep disorders: practical management for the pediatrician.

Current opinion in pediatrics·2026
Same journal

Advanced therapies in management of pediatric inflammatory bowel disease.

Current opinion in pediatrics·2026
Same journal

Artificial intelligence in pediatric endoscopy for hereditary polyposis syndromes: promises and challenges.

Current opinion in pediatrics·2026
Same journal

Hormonal acne therapies in pediatrics.

Current opinion in pediatrics·2026
Same journal

Clinical implementation of artificial intelligence in adolescent mental healthcare.

Current opinion in pediatrics·2026
See all related articles

Related Experiment Video

Updated: May 14, 2026

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells
06:29

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Published on: January 29, 2014

Complement disorders and hemolytic uremic syndrome.

Catherine Joseph1, Jyothsna Gattineni

  • 1Department of Pediatrics, University of Texas, Southwestern Medical Center, Dallas, Texas 75390-9063, USA.

Current Opinion in Pediatrics
|February 13, 2013
PubMed
Summary
This summary is machine-generated.

Complement-mediated hemolytic uremic syndrome (aHUS) has a worse prognosis than STEC-HUS. Early identification and plasma therapy are crucial for better outcomes, with eculizumab and transplantation offering new hope.

More Related Videos

Depletion of Specific Cell Populations by Complement Depletion
06:17

Depletion of Specific Cell Populations by Complement Depletion

Published on: February 5, 2010

Measuring the 50% Haemolytic Complement (CH50) Activity of Serum
08:26

Measuring the 50% Haemolytic Complement (CH50) Activity of Serum

Published on: March 29, 2010

Related Experiment Videos

Last Updated: May 14, 2026

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells
06:29

Methods for Quantitative Detection of Antibody-induced Complement Activation on Red Blood Cells

Published on: January 29, 2014

Depletion of Specific Cell Populations by Complement Depletion
06:17

Depletion of Specific Cell Populations by Complement Depletion

Published on: February 5, 2010

Measuring the 50% Haemolytic Complement (CH50) Activity of Serum
08:26

Measuring the 50% Haemolytic Complement (CH50) Activity of Serum

Published on: March 29, 2010

Area of Science:

  • Nephrology
  • Hematology
  • Immunology

Background:

  • Complement-mediated hemolytic uremic syndrome (aHUS) represents a significant portion of non-Shiga toxin-associated HUS cases.
  • Understanding the genetic basis of aHUS has advanced with the identification of novel mutations in complement-regulating proteins.

Purpose of the Study:

  • To review the pathophysiology, clinical manifestations, and therapeutic strategies for aHUS.
  • To highlight the importance of early diagnosis and intervention in aHUS management.

Main Methods:

  • Literature review of pathophysiology, clinical features, and treatment options for aHUS.
  • Analysis of recent findings on genetic mutations and their impact on aHUS.

Main Results:

  • Identification of numerous disease-causing mutations in complement-regulating proteins over the past decade.
  • aHUS demonstrates a poorer prognosis compared to Shiga toxin-mediated HUS, frequently leading to end-stage renal disease.

Conclusions:

  • Early aHUS identification is critical for initiating plasma therapy.
  • Plasma therapy and eculizumab offer improved prognosis for aHUS patients.
  • Combined liver-kidney transplantation is a promising option for managing aHUS, despite high recurrence risk post-transplant.